Expand allCollapse all
Class Actions
Confidential: Defending an app platform in class action proceedings commenced on behalf of consumers and developers seeking compensation arising from alleged overpayments on in-app purchases.
Volkswagen Emissions: Greg defended the VW Group in five class actions in the Federal Court of Australia, brought by two plaintiff law firms on behalf of vehicle owners and the ACCC in respect of diesel emissions issues and regulatory issues. An in-principle settlement was reached in the class actions in September 2019 and approved by the Court in April 2020.
Subaru – Takata Class Action: Greg acted for Subaru Australia in the defence of the Takata Airbag class actions, which involved separate class actions against several OEMs, covering more than a million vehicles subject to the Takata Airbag compulsory recall. The parties to all but one of those class actions negotiated a settlement with the plaintiffs which was approved by the NSW Supreme Court in June 2022.
Hino Motors Ltd (Hino Motors): Defending Hino Motors in a class action in relation to alleged misconduct concerning engine certification of certain Hino diesel vehicles.
Bayer: Greg is acting for Bayer in a class action commenced in the Victorian Supreme Court relating to the Essure contraceptive device. A trial of the lead Plaintiff's claim and certain common issues will commence on 11 April 2023.
Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): Greg acted in what is considered to be the largest product liability class action in Australia in the successful defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor. On 11 May 2012, the firm secured a historic High Court win in these proceedings. Greg acted as junior counsel at the three month long first instance trial.
Storm Financial: Greg led the team acting for the Commonwealth Bank of Australia in its defence of a class action brought by former clients of Storm Financial in the Queensland Registry of the Federal Court. The trial ran for eight months and encompassed more than 60 sitting days. The matter ultimately settled in late 2014 before judgment was handed down.
Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).
Dust Diseases Tribunal of NSW: Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.
Personal injury litigation: Greg had appeared for and advised defendants in personal injury claims ranging from product liability, through industrial accidents, motor vehicle collisions and aircraft accidents.
See Class Actions
Product Liability
Volkswagen Emissions: Greg defended the VW Group in five class actions in the Federal Court of Australia, brought by two plaintiff law firms on behalf of vehicle owners and the ACCC in respect of diesel emissions issues and regulatory issues. An in-principle settlement was reached in the class actions in September 2019 and approved by the Court in April 2020.
Subaru – Takata Class Action: Greg acted for Subaru Australia in the defence of the Takata Airbag class actions, which involved separate class actions against several OEMs, covering more than a million vehicles subject to the Takata Airbag compulsory recall. The parties to all but one of those class actions negotiated a settlement with the plaintiffs which was approved by the NSW Supreme Court in June 2022.
Hino Motors Ltd (Hino Motors): Defending Hino Motors in a class action in relation to alleged misconduct concerning engine certification of certain Hino diesel vehicles.
Bayer: Greg is acting for Bayer in a class action commenced in the Victorian Supreme Court relating to the Essure contraceptive device. A trial of the lead Plaintiff's claim and certain common issues will commence on 11 April 2023.
Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): Greg acted in what is considered to be the largest product liability class action in Australia in the successful defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor. On 11 May 2012, the firm secured an historic High Court win in these proceedings. Greg acted as junior counsel at the three month long first instance trial.
Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).
Roche Products Pty Ltd: Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.
Personal injury litigation: Greg had appeared for and advised defendants in personal injury claims ranging from product liability, through industrial accidents, motor vehicle collisions and aircraft accidents.
Dust Diseases Tribunal of NSW: Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.
See Product Liability
Litigation and Dispute Resolution
Confidential: Defending an app platform in class action proceedings commenced on behalf of consumers and developers seeking compensation arising from alleged overpayments on in-app purchases.
Volkswagen Emissions: Greg defended the VW Group in five class actions in the Federal Court of Australia, brought by two plaintiff law firms on behalf of vehicle owners and the ACCC in respect of diesel emissions issues and regulatory issues. An in-principle settlement was reached in the class actions in September 2019 and approved by the Court in April 2020.
Subaru – Takata Class Action: Greg acted for Subaru Australia in the defence of the Takata Airbag class actions, which involved separate class actions against several OEMs, covering more than a million vehicles subject to the Takata Airbag compulsory recall. The parties to all but one of those class actions negotiated a settlement with the plaintiffs which was approved by the NSW Supreme Court in June 2022.
Hino Motors Ltd (Hino Motors): Defending Hino Motors in a class action in relation to alleged misconduct concerning engine certification of certain Hino diesel vehicles.
Bayer: Greg is acting for Bayer in a class action commenced in the Victorian Supreme Court relating to the Essure contraceptive device. A trial of the lead Plaintiff's claim and certain common issues will commence on 11 April 2023.
Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): Greg acted in what is considered to be the largest product liability class action in Australia in the successful defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor. On 11 May 2012, the firm secured an historic High Court win in these proceedings. Greg acted as junior counsel at the three month long first instance trial.
Storm Financial: Greg led the team acting for the Commonwealth Bank of Australia in its defence of a class action brought by former clients of Storm Financial in the Queensland Registry of the Federal Court. The trial ran for eight months and encompassed more than 60 sitting days. The matter ultimately settled in late 2014 before judgment was handed down.
CBA – Financial Advice: Advised the Commonwealth Bank of Australia (CBA) in relation to the establishment and conduct of its Advice Review Program. The program involves CBA reviewing financial advice it has previously provided to Customers and making them offers of compensation for inappropriate advice, is the largest program of its kind in Australia.
Novartis Pharmaceuticals Australia Pty Ltd: Advised in relation to litigation against the Department of Health in respect of the Minister's refusal to exercise discretion to reverse a price reduction.
See Litigation and Dispute Resolution
Pharmaceutical and Medical Devices
Pharmaceutical Benefits Scheme: Greg advises clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.
Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): Greg acted in what is considered to be the largest product liability class action in Australia in the successful defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor. On 11 May 2012, the firm secured an historic High Court win in these proceedings. Greg acted as junior counsel at the three month long first instance trial.
Janssen-Cilag: Greg represented Janssen in an AAT challenge to the TGA's approval of a biosimilar's product information.
Roche Products Pty Ltd: Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.
Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).
Relationships with healthcare professionals: Greg has assisted international device manufacturers with physician engagement in Australia, including advice in relation to fellowship arrangements and speaker and consultant agreements.
Advertising disputes: Greg has acted for medical device companies in advertising disputes, including disputes with competitors referred to relevant industry dispute resolution Tribunals and complaints to the TGA's Complaints Resolution Panel.
Engagement with regulators: Greg has worked with a number of medical device companies on their engagement with regulators. This work has included: providing advice about Australia's medical device classification rules, assisting to prepare submissions to the TGA on a range of issues, including enforcement actions and applications to amend indications and assisting a company to respond to allegations by the Australian Health Practitioner Regulation Agency that it was improperly influencing health practitioners' patient care.
Novartis Pharmaceuticals Australia Pty Ltd: Advised in relation to litigation against the Department of Health in respect of the Minister's refusal to exercise discretion to reverse a price reduction.
Greg has also assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers. The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint.
See Pharmaceutical and Medical Devices
Healthcare and Life Sciences
Bayer: Greg is acting for Bayer in a class action commenced in the Victorian Supreme Court relating to the Essure contraceptive device. A trial of the lead Plaintiff's claim and certain common issues will commence on 11 April 2023.
Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited (MSDA): Greg acted in what is considered to be the largest product liability class action in Australia in the successful defence of representative proceedings involving claimants alleging to have suffered cardiovascular injuries due to their consumption of VIOXX, a COX-2 inhibitor. On 11 May 2012, the firm secured an historic High Court win in these proceedings. Greg acted as junior counsel at the three month-long first instance trial.
Janssen-Cilag: Greg represented Janssen in an AAT challenge to the TGA's approval of a biosimilar's product information.
Pharmaceutical Benefits Scheme: Greg advises clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.
Roche Products Pty Ltd: Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.
Gravigard (Copper 7) intrauterine contraceptive device (IUD): Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).
Relationships with healthcare professionals: Greg has assisted international device manufacturers with physician engagement in Australia, including advice in relation to fellowship arrangements and speaker and consultant agreements.
Advertising disputes: Greg has acted for medical device companies in advertising disputes, including disputes with competitors referred to relevant industry dispute resolution Tribunals and complaints to the TGA's Complaints Resolution Panel.
Engagement with regulators: Greg has worked with a number of medical device companies on their engagement with regulators. This work has included: providing advice about Australia's medical device classification rules, assisting to prepare submissions to the TGA on a range of issues, including enforcement actions and applications to amend indications and assisting a company to respond to allegations by the Australian Health Practitioner Regulation Agency that it was improperly influencing health practitioner's patient care.
Pharmaceutical pricing issues: Greg advises numerous pharmaceutical clients in relation to strategy for and legal issues arising from their dealings with the Pharmaceutical Benefits Division and Pharmaceutical Benefits Advisory Committee, bodies responsible for the reimbursement arrangements for pharmaceutical products in Australia. This has included advice about the effects of biosimilarity on the reimbursement of originator pharmaceuticals.
Novartis Pharmaceuticals Australia Pty Ltd: Advised in relation to litigation against the Department of Health in respect of the Minister's refusal to exercise discretion to reverse a price reduction.
Greg has also assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers. The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint.